Erasca Inc
Company Profile
Business description
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Contact
3115 Merryfield Row
Suite 300
San DiegoCA92121
USAT: +1 858 465-6511
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
103
Stocks News & Analysis
stocks
Cheap retail REIT with an attractive yield
stocks
Expanding store network for ASX listed retailer
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,131.30 | 71.80 | 0.79% |
| CAC 40 | 8,444.64 | 60.63 | 0.72% |
| DAX 40 | 24,973.49 | 79.48 | 0.32% |
| Dow JONES (US) | 51,671.03 | 468.77 | 0.92% |
| FTSE 100 | 10,496.96 | 66.34 | 0.64% |
| HKSE | 24,493.95 | 348.72 | -1.40% |
| NASDAQ | 26,683.94 | 795.10 | 3.07% |
| Nikkei 225 | 69,404.50 | 87.00 | 0.13% |
| NZX 50 Index | 13,426.13 | 65.54 | 0.49% |
| S&P 500 | 7,554.29 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,917.70 | 77.30 | 0.87% |
| SSE Composite Index | 4,091.89 | 4.58 | -0.11% |